🎉 M&A multiples are live!
Check it out!

Equillium Valuation Multiples

Discover revenue and EBITDA valuation multiples for Equillium and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Equillium Overview

About Equillium

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.


Founded

2017

HQ

United States of America
Employees

35

Financials

LTM Revenue $29.3M

LTM EBITDA n/a

EV

-$4.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Equillium Financials

Equillium has a last 12-month revenue of $29.3M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Equillium achieved revenue of $41.1M and an EBITDA of -$7.6M.

Equillium expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Equillium valuation multiples based on analyst estimates

Equillium P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $36.1M $41.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$12.1M -$7.6M XXX XXX XXX
EBITDA Margin -34% -18% XXX XXX XXX
Net Profit -$62.4M -$13.3M XXX XXX XXX
Net Margin -173% -32% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Equillium Stock Performance

As of April 15, 2025, Equillium's stock price is $0.

Equillium has current market cap of $17.4M, and EV of -$4.8M.

See Equillium trading valuation data

Equillium Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$4.8M $17.4M XXX XXX XXX XXX $-0.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Equillium Valuation Multiples

As of April 15, 2025, Equillium has market cap of $17.4M and EV of -$4.8M.

Equillium's trades at -0.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Equillium's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Equillium and 10K+ public comps

Equillium Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$4.8M XXX XXX XXX
EV/Revenue -0.1x XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -2.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Equillium Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Equillium Valuation Multiples

Equillium's NTM/LTM revenue growth is -100%

Equillium's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Equillium's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Equillium's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Equillium and other 10K+ public comps

Equillium Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 14% XXX XXX XXX XXX
EBITDA Margin -18% XXX XXX XXX XXX
EBITDA Growth -38% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $1.2M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 29% XXX XXX XXX XXX
R&D Expenses to Revenue 91% XXX XXX XXX XXX
Opex to Revenue 120% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Equillium Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Equillium M&A and Investment Activity

Equillium acquired  XXX companies to date.

Last acquisition by Equillium was  XXXXXXXX, XXXXX XXXXX XXXXXX . Equillium acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Equillium

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Equillium

When was Equillium founded? Equillium was founded in 2017.
Where is Equillium headquartered? Equillium is headquartered in United States of America.
How many employees does Equillium have? As of today, Equillium has 35 employees.
Who is the CEO of Equillium? Equillium's CEO is Mr. Bruce D. Steel.
Is Equillium publicy listed? Yes, Equillium is a public company listed on NAS.
What is the stock symbol of Equillium? Equillium trades under EQ ticker.
When did Equillium go public? Equillium went public in 2018.
Who are competitors of Equillium? Similar companies to Equillium include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Equillium? Equillium's current market cap is $17.4M
What is the current revenue of Equillium? Equillium's last 12-month revenue is $29.3M.
What is the current EV/Revenue multiple of Equillium? Current revenue multiple of Equillium is -0.2x.
What is the current revenue growth of Equillium? Equillium revenue growth between 2023 and 2024 was 14%.
Is Equillium profitable? Yes, Equillium is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.